KR20240021188A - 체크포인트 키나제 1(chk1) 억제제 및 그의 용도 - Google Patents
체크포인트 키나제 1(chk1) 억제제 및 그의 용도 Download PDFInfo
- Publication number
- KR20240021188A KR20240021188A KR1020237044236A KR20237044236A KR20240021188A KR 20240021188 A KR20240021188 A KR 20240021188A KR 1020237044236 A KR1020237044236 A KR 1020237044236A KR 20237044236 A KR20237044236 A KR 20237044236A KR 20240021188 A KR20240021188 A KR 20240021188A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- tautomer
- stereoisomer
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193990P | 2021-05-27 | 2021-05-27 | |
| US63/193,990 | 2021-05-27 | ||
| PCT/US2022/031141 WO2022251502A1 (en) | 2021-05-27 | 2022-05-26 | Checkpoint kinase 1 (chk1) inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240021188A true KR20240021188A (ko) | 2024-02-16 |
Family
ID=84229213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237044236A Pending KR20240021188A (ko) | 2021-05-27 | 2022-05-26 | 체크포인트 키나제 1(chk1) 억제제 및 그의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11707462B2 (https=) |
| EP (1) | EP4347582A4 (https=) |
| JP (1) | JP2024520481A (https=) |
| KR (1) | KR20240021188A (https=) |
| CN (1) | CN117715905A (https=) |
| AU (1) | AU2022282384A1 (https=) |
| BR (1) | BR112023024571A2 (https=) |
| CA (1) | CA3219348A1 (https=) |
| IL (1) | IL308759A (https=) |
| MX (1) | MX2023014028A (https=) |
| TW (1) | TW202313588A (https=) |
| WO (1) | WO2022251502A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3187760A1 (en) | 2020-08-12 | 2022-02-17 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
| TW202237586A (zh) | 2020-11-30 | 2022-10-01 | 日商住友製藥股份有限公司 | 5-雜芳基-1h-吡唑-3-胺衍生物 |
| BR112023024571A2 (pt) | 2021-05-27 | 2024-02-06 | Boundless Bio Inc | Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos |
| AU2022421580A1 (en) * | 2021-12-24 | 2024-07-18 | Sumitomo Pharma Co., Ltd. | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| CN119546588A (zh) * | 2022-05-24 | 2025-02-28 | 无界生物公司 | 吡啶检查点激酶1（chk1）抑制剂及其用途 |
| WO2023226658A1 (en) * | 2022-05-25 | 2023-11-30 | Sperogenix Therapeutics Limited | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof |
| TW202440549A (zh) * | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| JP2025540059A (ja) * | 2022-11-29 | 2025-12-11 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤の組合せおよびその使用 |
| WO2024196923A1 (en) * | 2023-03-20 | 2024-09-26 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| WO2024211271A1 (en) * | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| WO2024211270A1 (en) * | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor crystalline form and uses thereof |
| WO2025030049A1 (en) * | 2023-08-02 | 2025-02-06 | Health Research, Inc. | Sequential treatment method for p53-deficient cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02010222A (es) * | 2000-04-18 | 2003-05-23 | Agouron Pharma | Pirazoles para inhibir proteina cinasa. |
| NZ523656A (en) * | 2000-08-31 | 2004-11-26 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN108601781B (zh) * | 2016-02-04 | 2019-11-22 | 广州必贝特医药技术有限公司 | 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用 |
| US12428395B2 (en) * | 2019-08-01 | 2025-09-30 | Sperogenix Therapeutics Limited | Heterocyclic compounds as kinase inhibitor and uses thereof |
| CN112457306A (zh) * | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| CN111253370B (zh) | 2020-03-24 | 2021-08-03 | 浙江大学 | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 |
| DK4168401T3 (da) * | 2020-06-19 | 2026-04-13 | Anaxis Pharma Pty Ltd | Sulfonamidforbindelser |
| CA3187760A1 (en) | 2020-08-12 | 2022-02-17 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
| KR20230092972A (ko) | 2020-10-23 | 2023-06-26 | 셀진 코포레이션 | 연충 감염 및 질병의 치료를 위한 헤테로환식 화합물 및 이들의 용도 |
| TW202237586A (zh) * | 2020-11-30 | 2022-10-01 | 日商住友製藥股份有限公司 | 5-雜芳基-1h-吡唑-3-胺衍生物 |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| BR112023024571A2 (pt) | 2021-05-27 | 2024-02-06 | Boundless Bio Inc | Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos |
| AU2022421580A1 (en) | 2021-12-24 | 2024-07-18 | Sumitomo Pharma Co., Ltd. | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| CN119546588A (zh) | 2022-05-24 | 2025-02-28 | 无界生物公司 | 吡啶检查点激酶1（chk1）抑制剂及其用途 |
| WO2023226658A1 (en) | 2022-05-25 | 2023-11-30 | Sperogenix Therapeutics Limited | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof |
| WO2023229032A1 (ja) | 2022-05-27 | 2023-11-30 | 住友ファーマ株式会社 | 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬 |
| JP2025540059A (ja) | 2022-11-29 | 2025-12-11 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤の組合せおよびその使用 |
| TW202440549A (zh) | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| WO2024196923A1 (en) | 2023-03-20 | 2024-09-26 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| WO2024211271A1 (en) | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| WO2024211270A1 (en) | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor crystalline form and uses thereof |
-
2022
- 2022-05-26 BR BR112023024571A patent/BR112023024571A2/pt unknown
- 2022-05-26 JP JP2023573047A patent/JP2024520481A/ja active Pending
- 2022-05-26 EP EP22812165.3A patent/EP4347582A4/en active Pending
- 2022-05-26 WO PCT/US2022/031141 patent/WO2022251502A1/en not_active Ceased
- 2022-05-26 CN CN202280052765.2A patent/CN117715905A/zh active Pending
- 2022-05-26 MX MX2023014028A patent/MX2023014028A/es unknown
- 2022-05-26 TW TW111119737A patent/TW202313588A/zh unknown
- 2022-05-26 CA CA3219348A patent/CA3219348A1/en active Pending
- 2022-05-26 KR KR1020237044236A patent/KR20240021188A/ko active Pending
- 2022-05-26 AU AU2022282384A patent/AU2022282384A1/en active Pending
- 2022-05-26 IL IL308759A patent/IL308759A/en unknown
- 2022-08-29 US US17/897,667 patent/US11707462B2/en active Active
-
2023
- 2023-06-01 US US18/327,775 patent/US12527790B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230310423A1 (en) | 2023-10-05 |
| EP4347582A1 (en) | 2024-04-10 |
| US11707462B2 (en) | 2023-07-25 |
| AU2022282384A1 (en) | 2023-12-14 |
| CN117715905A (zh) | 2024-03-15 |
| US12527790B2 (en) | 2026-01-20 |
| EP4347582A4 (en) | 2025-05-07 |
| JP2024520481A (ja) | 2024-05-24 |
| TW202313588A (zh) | 2023-04-01 |
| IL308759A (en) | 2024-01-01 |
| WO2022251502A1 (en) | 2022-12-01 |
| CA3219348A1 (en) | 2022-12-01 |
| BR112023024571A2 (pt) | 2024-02-06 |
| MX2023014028A (es) | 2023-12-12 |
| US20230026313A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11707462B2 (en) | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | |
| AU2023275712A1 (en) | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| WO2024118564A1 (en) | Checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| TW202039489A (zh) | Mat2a之雜雙環抑制劑及用於治療癌症之使用方法 | |
| CN107922431A (zh) | Hpk1抑制剂及其使用方法 | |
| CA2915622A1 (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
| KR20130129244A (ko) | 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도 | |
| WO2013170770A1 (zh) | 具有抗肿瘤活性的乙炔衍生物 | |
| WO2025049814A2 (en) | Ribonucleotide reductase (rnr) compositions and methods of use | |
| BR112017003312B1 (pt) | Compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos | |
| EP3556761B1 (en) | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | |
| JP2016527184A (ja) | Ｓｌｃ２ａ輸送体阻害剤 | |
| KR20240101555A (ko) | 사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도 | |
| WO2022187200A1 (en) | Ribonucleotide reductase (rnr) inhibitors and uses thereof | |
| WO2023043938A1 (en) | Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof | |
| EP4626433A1 (en) | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof | |
| EA051928B1 (ru) | Пиридиновые ингибиторы киназы 1 контрольной точки (chk1) и их применение | |
| TWI423974B (zh) | 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用 | |
| JP2025531147A (ja) | 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用 | |
| TW201305153A (zh) | 三唑並吡啶和三唑並吡嗪化合物及其組合物和應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231221 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250508 Comment text: Request for Examination of Application |